Phillip Gambel

Array ( [id] => 13428105 [patent_doc_number] => 20180265595 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => ANTI-CD19 scFv (FMC63) POLYPEPTIDE AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/912265 [patent_app_country] => US [patent_app_date] => 2018-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22168 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15912265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13734159 [patent_doc_number] => 20180371547 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration [patent_app_type] => utility [patent_app_number] => 15/912379 [patent_app_country] => US [patent_app_date] => 2018-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19953 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15912379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18085550 [patent_doc_number] => 11535668 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-27 [patent_title] => Inducible monovalent antigen binding protein [patent_app_type] => utility [patent_app_number] => 16/489523 [patent_app_country] => US [patent_app_date] => 2018-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 14257 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16489523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12909061 [patent_doc_number] => 20180194862 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => BISPECIFIC BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 15/903812 [patent_app_country] => US [patent_app_date] => 2018-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41621 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15903812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13357389 [patent_doc_number] => 20180230234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => INHIBITION OF THE COMPLEMENT SYSTEM [patent_app_type] => utility [patent_app_number] => 15/902629 [patent_app_country] => US [patent_app_date] => 2018-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17954 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15902629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12885142 [patent_doc_number] => 20180186889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => ANTI-CD40 ANTIBODIES AND THEIR USES [patent_app_type] => utility [patent_app_number] => 15/901560 [patent_app_country] => US [patent_app_date] => 2018-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22178 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15901560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15209825 [patent_doc_number] => 20190367599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OR PREVENTION OF A C5-RELATED DISEASE AND A METHOD FOR TREATING OR PREVENTING A C5-RELATED DISEASE [patent_app_type] => utility [patent_app_number] => 16/480047 [patent_app_country] => US [patent_app_date] => 2018-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16192 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16480047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13194109 [patent_doc_number] => 10111958 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-30 [patent_title] => Anti-CD40 antibody formulation [patent_app_type] => utility [patent_app_number] => 15/881195 [patent_app_country] => US [patent_app_date] => 2018-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12540 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15881195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15038595 [patent_doc_number] => 20190330302 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => CHIMERIC ANTIGEN RECEPTORS BASED ON ALTERNATIVE SIGNAL I DOMAINS [patent_app_type] => utility [patent_app_number] => 16/476588 [patent_app_country] => US [patent_app_date] => 2018-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24298 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16476588 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15117147 [patent_doc_number] => 20190345206 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => Compositions and Methods Related to Engineered Fc Constructs [patent_app_type] => utility [patent_app_number] => 16/474640 [patent_app_country] => US [patent_app_date] => 2018-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54301 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16474640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13339885 [patent_doc_number] => 20180221482 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => USE OF ANTIBODIES AGAINST ICAM-1 IN COMBINATION WITH AN ANTI CANCER DRUG IN THE TREATMENT OF PATIENTS [patent_app_type] => utility [patent_app_number] => 15/846419 [patent_app_country] => US [patent_app_date] => 2017-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26588 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15846419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12637467 [patent_doc_number] => 20180104319 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => METHODS OF TREATING ANTIBODY-MEDIATED REJECTION IN ORGAN TRANSPLANT PATIENTS WITH C1-ESTERASE INHIBITOR [patent_app_type] => utility [patent_app_number] => 15/844850 [patent_app_country] => US [patent_app_date] => 2017-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7752 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15844850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14516499 [patent_doc_number] => 10335485 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-02 [patent_title] => Anti-VLA-4 antibodies [patent_app_type] => utility [patent_app_number] => 15/838884 [patent_app_country] => US [patent_app_date] => 2017-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 15 [patent_no_of_words] => 15889 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15838884 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12585042 [patent_doc_number] => 20180086843 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => ANTI-CD22 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/837944 [patent_app_country] => US [patent_app_date] => 2017-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26891 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15837944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12425052 [patent_doc_number] => 09974855 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-22 [patent_title] => Humanized anti-CD40 antibodies and methods of administering thereof [patent_app_type] => utility [patent_app_number] => 15/829352 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 25 [patent_no_of_words] => 27099 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15829352 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12707023 [patent_doc_number] => 20180127507 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => METHODS OF TREATING PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS [patent_app_type] => utility [patent_app_number] => 15/804108 [patent_app_country] => US [patent_app_date] => 2017-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26017 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15804108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13551897 [patent_doc_number] => 20180327496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => ANTI-CD40 ANTIBODIES IN COMBINATION AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/801901 [patent_app_country] => US [patent_app_date] => 2017-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29389 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15801901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13763549 [patent_doc_number] => 10174109 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-08 [patent_title] => Method for producing human monoclonal antibodies that binds to at least one part of HMGB1 [patent_app_type] => utility [patent_app_number] => 15/798478 [patent_app_country] => US [patent_app_date] => 2017-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5386 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15798478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12681031 [patent_doc_number] => 20180118843 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/794090 [patent_app_country] => US [patent_app_date] => 2017-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28516 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15794090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12233172 [patent_doc_number] => 20180066036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-08 [patent_title] => 'SINGLE-CHAIN CD40-RECEPTOR AGONIST PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/795020 [patent_app_country] => US [patent_app_date] => 2017-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 16618 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15795020 [rel_patent_id] =>[rel_patent_doc_number] =>)